AI Is Advancing Pharma Logistics. But Is the Industry Ready to Share Its Data?
Artificial intelligence promises smarter, more resilient pharmaceutical supply chains. Yet discussions at Airfreight Pharma 2026 in Athens highlighted a fundamental challenge: technology is advancing faster than the industry’s ability to share, interpret and act on data.
Pharmaceutical airfreight has never had access to more information. Temperature monitoring, shipment tracking, predictive analytics and increasingly sophisticated digital tools are creating new opportunities to understand and manage supply-chain risks.
But more data does not automatically mean better decisions.
At Airfreight Pharma 2026, hosted in Athens with the participation of the Cool Chain Association (CCA), industry stakeholders explored how artificial intelligence, data transparency and operational expertise could improve product protection and supply-chain resilience.
A recurring theme was clear: the real challenge is not simply collecting data, but turning it into trusted, actionable intelligence across the entire supply chain.
The Data Sharing Dilemma
Pharmaceutical shipments pass through multiple organisations, each responsible for a different stage of the journey.
Manufacturers, freight forwarders, airlines, ground handlers and transport providers all generate valuable operational data. Yet that information is often held in separate systems, governed by different commercial agreements and subject to varying data protection requirements.
Data governance and security are essential, particularly in a highly regulated industry. However, these requirements can also make it difficult to share the information needed to develop a complete picture of shipment performance.
The result is a paradox: the industry is investing heavily in visibility, while the information required to make end-to-end decisions may remain fragmented.
The discussions in Athens highlighted the need to move beyond simply increasing the volume of available data towards establishing greater clarity over what information is needed, who can access it and how it can be used responsibly.
Greater transparency does not necessarily mean sharing everything. It means sharing the right information, with the right stakeholders, at the right time.
AI Can Identify Risks. People Must Still Make Decisions.
Artificial intelligence and digital simulation offer significant potential for pharmaceutical logistics.
During the event, participants explored how digital twins could help assess operational variables, simulate disruptions and understand how different conditions might affect temperature-controlled shipments.
Such capabilities could support more informed lane qualification, improved contingency planning and better identification of potential failure points.
However, the quality of any AI-driven insight depends on the reliability and relevance of the underlying data.
A temperature reading without sufficient operational context may not explain what happened to a shipment, why it happened or what action should follow.
Product stability, packaging performance, route conditions and handling procedures must all be considered before interpreting the significance of an event.
The discussions also reinforced the importance of human judgement.
When a shipment is delayed on the tarmac or an unexpected operational disruption occurs, the time available to intervene may be measured in minutes.
Data can alert stakeholders to a developing risk, but trained personnel must understand the situation, assess the options and act.
This makes continued investment in people, training and operational decision-making just as important as investment in technology.
From Visibility to Evidence-Based Trust
For pharmaceutical manufacturers, visibility is valuable, but it is not the ultimate objective.
The priority is protecting product integrity and ensuring that medicines reach patients safely.
During the cool-corridor discussions, participants repeatedly emphasised that confidence in a logistics process must be supported by evidence.
Temperature records, qualification studies, operational performance data, deviation histories and demonstrated risk controls all contribute to that confidence.
AI and analytics can help organisations interpret this information and identify opportunities for improvement. But technology cannot replace the need for reliable evidence that a process performs consistently.
This distinction becomes particularly important when evaluating temperature-controlled corridors.
A route that performs well under one set of conditions may behave differently during another season, with different packaging or when operational arrangements change.
Understanding these variables requires more than an isolated dataset. It requires collaboration between the organisations responsible for each stage of the journey.
Collaboration Is the Next Step
The pharmaceutical logistics industry has made considerable progress in monitoring technology, digitalisation and data collection.
The next opportunity lies in connecting those capabilities more effectively.
This does not require organisations to abandon commercial confidentiality or compromise data protection. It requires a shared understanding of which information is essential for product protection, how it should be governed and how it can support collective learning.
Through its community of stakeholders across the temperature-controlled supply chain, the Cool Chain Association has an important role in encouraging these conversations.
Better collaboration around data could help the industry identify recurring operational weaknesses, improve procedures, strengthen lane qualification and reduce avoidable inefficiencies.
It could also help organisations move from reacting to individual shipment problems towards understanding and addressing their underlying causes.
That is where the potential of AI becomes particularly valuable: not simply predicting what might go wrong, but helping the industry learn how to prevent it.
Technology Will Advance. Trust Must Be Earned.
The discussions at Airfreight Pharma 2026 demonstrated that artificial intelligence will continue to influence the future of pharmaceutical logistics.
But successful adoption will require more than investment in algorithms, platforms and monitoring devices.
It will require high-quality data, responsible governance, transparent collaboration and continued investment in the people who interpret information and make critical decisions.
The industry’s opportunity is not simply to become more data-driven. It is to become more evidence-driven, more collaborative and ultimately more predictable.
Because in pharmaceutical logistics, better decisions are not just about efficiency.
They are about protecting products, reducing risk and maintaining the trust of the patients who depend on them.







